LifeTech Capital issues STEM Report Update April 2, 2012
uCNS-SC® Phase I PMD Data in Children Shows Unprecedented Results Myelination Continued Increasing 3-Months Post-Immunosuppression Gains in Motor and/or Cognitive Function in 3 out of 4 Children
Download Full 8-Page Note with Important Disclosures: Morning Note 04-02-12 STEM NOTE: StemCells Inc. will host a live conference call and webcast today, April 2, at 11:00 AM Eastern Time (8:00 AM Pacific Time) to discuss the summary trial results.
StemCells Inc. announced successful preliminary Phase I data in Pelizaeus-Merzbacher Disease (PMD), a rare hypo-myelination disorder in children. A summary of the trial results were presented March 31st at the 2012 European Leukodystrophy Association (ELA) Families/Scientists Meeting in Paris. StemCells Inc. now intends to proceed to Phase II clinical trials. Highlights of the results are:
• Progressive and durable donor-cell derived myelination in all 4 patients
• Small but measureable gains in motor and/or cognitive function in 3 of the 4 patients (the 4th patient remained clinically stable)
• After 1 year, MRI showed changes compatible with increased myelination in the region of the transplantation. The MRI signs of myelination persisted even after immunosuppression was stopped at 9 months and in fact, were also found to progress over time.
• The development of new myelin signals is unprecedented in patients with connatal PMD and is consistent with HuCNS-SC engraftment. These results may also be applicable to other leukodystrophies, as well as more common myelin disorders including transverse myelitis, multiple sclerosis and periventricular white matter injury seen in Cerebral Palsy.